Compare First Trust Cloud Computing ETF (SKYY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? First Trust Cloud Computing ETF trades at $162.16 (market cap $3.56B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.1× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 84 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SKYY | SYRE | |
|---|---|---|
Market Cap | $3.56B | $7.35B |
Volume | 272,580 | 1,624,631 |
52-Week High | $174.89 | $108.92 |
52-Week Low | $104.16 | $22.18 |
Typical Hold Time | 84 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Trust Cloud Computing ETF (SKYY) trades at $171.52, down 0.57% on the day but remains near its 52-week high of $169.41. Technical indicators show a bullish trend with strong moving average support, though RSI suggests mild overbought conditions. The ETF provides diversified exposure to cloud computing companies benefiting from AI adoption and digital transformation trends, with recent articles highlighting the sector's growth potential.
The cloud computing sector shows strong secular growth drivers including AI infrastructure spending and cloud migration. While technical momentum remains positive, investors should monitor valuation levels given the ETF's proximity to recent highs. Sector concentration and technology volatility present key risks, though institutional interest in cloud infrastructure remains robust.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
